about
Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and PerspectivesDepot-Based Delivery Systems for Pro-Angiogenic Peptides: A ReviewExtracellular matrix and growth factor engineering for controlled angiogenesis in regenerative medicineTherapeutic angiogenesis: controlled delivery of angiogenic factors.High-resolution harmonics ultrasound imaging for non-invasive characterization of wound healing in a pre-clinical swine model.Controlled delivery of sonic hedgehog morphogen and its potential for cardiac repairS100A1 deficiency impairs postischemic angiogenesis via compromised proangiogenic endothelial cell function and nitric oxide synthase regulationCombined transfer of human VEGF165 and HGF genes renders potent angiogenic effect in ischemic skeletal muscleCell therapy for cardiac repair--lessons from clinical trials.Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia.Adeno-associated virus serotype 9-mediated overexpression of extracellular superoxide dismutase improves recovery from surgical hind-limb ischemia in BALB/c mice.Systems biology of pro-angiogenic therapies targeting the VEGF systemGene therapy from the perspective of systems biology.A visible, targeted high-efficiency gene delivery and transfection strategyImpact of Cell Therapy on Myocardial Perfusion and Cardiovascular Outcomes in Patients With Angina Refractory to Medical Therapy: A Systematic Review and Meta-Analysis.Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells.Induction of aberrant vascular growth, but not of normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent.Controlled angiogenesis in the heart by cell-based expression of specific vascular endothelial growth factor levels.Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164The road ahead: working towards effective clinical translation of myocardial gene therapies.Vascular endothelial growth factor signaling in hypoxia and inflammation.Nanoscale strategies: treatment for peripheral vascular disease and critical limb ischemia.Effects of aging on angiogenesis.Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: a prospective nested case-control studyTumor vasculature targeting: a generally applicable approach for functionalized nanomaterials.Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis.In vivo assessment of peripheral vascular function by tcpO₂ and skin blood flow modelling.Supramolecular nanostructures that mimic VEGF as a strategy for ischemic tissue repairTreatment of mouse limb ischemia with an integrative hypoxia-responsive vector expressing the vascular endothelial growth factor gene.New vessel formation in the context of cardiomyocyte regeneration--the role and importance of an adequate perfusing vasculature.Angiogenic factor AGGF1 promotes therapeutic angiogenesis in a mouse limb ischemia modelpCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia.Inorganic nitrite and chronic tissue ischaemia: a novel therapeutic modality for peripheral vascular diseases.Pleiotrophin gene therapy for peripheral ischemia: evaluation of full-length and truncated gene variantsIdentification of a mechanism underlying regulation of the anti-angiogenic forkhead transcription factor FoxO1 in cultured endothelial cells and ischemic muscle.Lipo-chitin oligosaccharides, plant symbiosis signalling molecules that modulate mammalian angiogenesis in vitroQuantifying the vascular response to ischemia with speckle variance optical coherence tomographyQuantitative optical imaging of vascular response in vivo in a model of peripheral arterial disease.Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia.Injectable fibroblast growth factor-2 coacervate for persistent angiogenesis.
P2860
Q26769595-0D68A5FB-27B6-4824-BB2A-B0769C66DC07Q26799856-3F2EEEFC-43DA-4BFB-8703-7CBD57DF59A8Q26829783-5022A786-A601-46FD-875F-65A29B4E0838Q27023731-91DE574A-B8E3-414B-95AA-79D1387F74ABQ27310335-511356A9-3288-4B1F-A9B7-4EAC6333FD5AQ27321295-8A44FDB9-95D4-4432-B1AB-1169EC0B184AQ28276667-7840619C-CBDF-4C32-8F8D-AFAB91531F8CQ28728494-71FB986E-77F4-4352-8768-608C7FADCEE3Q30359782-D850B692-7CCC-4E6E-B346-5C79B452E849Q30413823-35CF18D8-DF30-4699-9EDF-011501E322FBQ30425244-ABF675A0-3000-4B74-8991-6DF7D85D3A88Q30430112-B712FC49-6399-42BA-B3D2-00B64F3AAC81Q30430438-8C84289F-6DB3-4BF4-8B91-AEDA8BFAD30CQ30475161-4EFA705A-8B16-43E6-8F7D-EEF007EEBE04Q30729604-3049C12D-5A41-4779-BA83-CDFB4F7311E4Q31005484-E38C29C4-6D0A-4A3B-BB3D-2E00BEC50BE5Q33586324-424F7967-8312-4A27-AAA0-1155DAD696CFQ33586957-2384565B-0434-458A-BAA7-0EE5F9D20CD3Q33627325-F32CFBB3-5C03-432E-AA85-AC56BB4CCB6CQ33705144-DDCAE9BF-63E4-4A29-BE95-E149680915BBQ33721685-B4965B0C-5957-465F-A899-B22B6D3961C4Q33864915-94B9E245-B152-4DE6-B04E-252458B0F9CBQ33914406-04786BEE-557F-402F-B133-5667BD92A9EFQ33932129-6CF29EA5-64E8-40CA-BCC8-DA99F50F8FD1Q34019838-D7E9A745-7E79-41FA-9F17-10A3FE911C93Q34068511-7F0FEA2A-FF08-4A04-98A1-A845060C4BAAQ34094164-2983E8A8-0EB9-4140-AE2A-341CE81F6E7CQ34205393-05842982-B566-4B14-8C1F-8A765642FE2AQ34217612-3A4E3305-B270-4C1C-87DE-CF230FC1E1AFQ34422460-CC2EB3AA-F5B9-4AEE-8145-F41E845D8B12Q34460354-F1BD3A6F-5A3E-4152-A0B1-F1141AB7DB6AQ34467088-A49DB61E-B6A8-4229-AA5A-C4E07B42DEB6Q34530182-6566C4E1-A994-4001-BF50-EE2F9816397EQ34695480-550DD65A-3ED5-4CF7-BE5A-15E20916C671Q34755828-ED3D485E-A42E-4382-91BE-78616FDAD362Q34764528-7989E84E-4B18-4E11-984A-B6A07655E9EAQ34848606-1E35A957-EC50-4DE9-9635-0BDCF2A9ABDFQ34954432-2B6901B5-44A7-4BA7-9D55-23C2F287A69AQ35007366-284B0994-4E01-4E7A-AE80-4246D1481A38Q35170697-6B09211F-20CB-43AA-83D5-F96F8D941415
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human studies of angiogenic gene therapy.
@en
Human studies of angiogenic gene therapy.
@nl
type
label
Human studies of angiogenic gene therapy.
@en
Human studies of angiogenic gene therapy.
@nl
prefLabel
Human studies of angiogenic gene therapy.
@en
Human studies of angiogenic gene therapy.
@nl
P2093
P2860
P1433
P1476
Human studies of angiogenic gene therapy.
@en
P2093
Douglas W Losordo
Jörn Tongers
Rajesh Gupta
P2860
P304
P356
10.1161/CIRCRESAHA.109.200386
P577
2009-10-01T00:00:00Z